You are here:

Ivabradine (Procoralan®)


Following a resubmission

ivabradine (Procoralan) is accepted for restricted use within NHS Scotland for the symptomatic treatment of chronic stable angina pectoris in patients with normal sinus rhythm for whom heart rate control is desirable and who have a contra-indication or intolerance for beta-blockers and rate-limiting calcium-channel blockers.

Non-inferiority of ivabradine versus a beta blocker and a calcium-channel blocker was shown in two controlled trials. Long-term protection against cardiovascular events, however, has not been demonstrated

Drug Details

Drug Name: Ivabradine (Procoralan®)
SMC Drug ID: 319/06
Manufacturer: Servier Laboratories Ltd
Indication: Chronic stable angina
BNF Category:
Sub Category: 2.6 Nitrates*** calcium-channel blockers*** and other antianginal drugs
Submission Type: Resubmission
Status: Restricted
Date Advice Published: 12 March 2007

Archived Advice

Full submission 9 October 2006